Home » Stocks » RDUS

Radius Health, Inc. (RDUS)

Stock Price: $19.80 USD 1.18 (6.34%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
Market Cap 896.97M
Revenue (ttm) 231.53M
Net Income (ttm) -112.54M
Shares Out 46.49M
EPS (ttm) -2.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $19.80
Previous Close $18.62
Change ($) 1.18
Change (%) 6.34%
Day's Open 19.12
Day's Range 19.00 - 20.11
Day's Volume 442,933
52-Week Range 10.15 - 23.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 6 days ago

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 week ago

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it will provide a corporate update at the 10th Annual SVB Leerink Global Healthcare Conferenc...

GlobeNewsWire - 1 week ago

BOSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter financial results on Thursday, February 25, 2021. The Company wil...

GlobeNewsWire - 1 week ago

BOSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a business update on the abaloparatide global business. Progress was made, and...

Zacks Investment Research - 1 week ago

5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty

Other stocks mentioned: ONCT, ORGO, TPTX, USNA
Seeking Alpha - 1 month ago

Radius Health announces the acquisition of the development and commercialization rights for RAD011 from Benuvia Therapeutics. The deal economics appear favorable and should add to the top-line...

Zacks Investment Research - 1 month ago

Radius (RDUS) is set to acquire the global development and commercialization rights of Benuvia Therapeutics' synthetic cannabidiol oral solution for utilization in multiple endocrine and metab...

GlobeNewsWire - 1 month ago

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Kelly Martin, President and CEO will present a virtual corporate update at the 39th Annual J....

Zacks Investment Research - 1 month ago

Radius (RDUS) signs an agreement with Paladin Labs, wherein the latter will now be responsible for all commercial activities related to Tymlos and abaloparatide-TD in Canada.

GlobeNewsWire - 1 month ago

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced a definitive agreement to acquire the global development and commercial...

GlobeNewsWire - 1 month ago

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that the Company has entered into definitive agreements with Endo Ventu...

GlobeNewsWire - 1 month ago

BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr. Andrew C. von Eschenbach have joined the ...

GlobeNewsWire - 2 months ago

WALTHAM, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since October 2020. The key...

Zacks Investment Research - 2 months ago

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 3 months ago

Radius (RDUS) reports an in-line loss but misses sales estimates in the third quarter.

Seeking Alpha - 3 months ago

Radius Health, Inc. (RDUS) CEO Kelly Martin on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Radius Health (RDUS) delivered earnings and revenue surprises of 0.00% and -5.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 3 months ago

Radius Health, Inc.'s (RDUS) CEO Kelly Martin on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the third quarter ended...

Zacks Investment Research - 3 months ago

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

WALTHAM, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since May 2020. The Company...

GlobeNewsWire - 4 months ago

WALTHAM, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020. The Compa...

GlobeNewsWire - 4 months ago

Schwartzman joins the newly formed Capital, Strategy, & Transactions Group Schwartzman joins the newly formed Capital, Strategy, & Transactions Group

GlobeNewsWire - 4 months ago

WALTHAM, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that the company has successfully sold its second oncology pipeline asset – RAD 140 - to El...

PRNewsWire - 5 months ago

WALTHAM, Mass. and FLORENCE, Italy, Sept. 25, 2020 /PRNewswire/ -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) and the Menarini Group today announced an update on the elaces...

GlobeNewsWire - 5 months ago

WALTHAM, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that Jose (Pepe) Carmona will be stepping down as Chief Fin...

Zacks Investment Research - 5 months ago

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 5 months ago

Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fract...

GlobeNewsWire - 5 months ago

Includes detailed results from Phase 2 histomorphometry study and Teijin’s Phase 3 trial in Japan Includes detailed results from Phase 2 histomorphometry study and Teijin’s Phase 3 trial in Japan

GlobeNewsWire - 5 months ago

WALTHAM, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced completion of enrollment in its “wearABLe” phase 3 trial.

GlobeNewsWire - 5 months ago

WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2020.

Zacks Investment Research - 6 months ago

Radius (RDUS) reports a wider-than-expected loss but beats sales estimates in the second quarter.

Seeking Alpha - 6 months ago

Radius Health, Inc.'s (RDUS) CEO Kelly Martin on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Radius Health (RDUS) delivered earnings and revenue surprises of -15.85% and 3.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 6 months ago

  Shares of Radius Health (NASDAQ:RDUS) rose 1.4% in pre-market trading after the company reported Q2 results.

GlobeNewsWire - 6 months ago

WALTHAM, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with...

Zacks Investment Research - 6 months ago

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 6 months ago

WALTHAM, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020. The Compa...

GlobeNewsWire - 7 months ago

WALTHAM, Mass. and FLORENCE, Italy, July 23, 2020 (GLOBE NEWSWIRE) -- The Menarini Group and Radius Health, Inc. (Nasdaq: RDUS) announced today that the companies have entered into an exclus...

Zacks Investment Research - 8 months ago

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 8 months ago

Radius partner Teijin Pharma has submitted a New Drug Application  for abaloparatide-SC for treatment of osteoporosis in Japan  

Seeking Alpha - 9 months ago

Radius Health, Inc. (RDUS) CEO Kelly Martin on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Radius (RDUS) reports wider-than-expected loss but beats sales estimates in the first quarter. The company lowers guidance for 2020.

Zacks Investment Research - 9 months ago

Radius Health (RDUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

WALTHAM, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors (the “Board”) granted G...

GlobeNewsWire - 9 months ago

Jesper Hoeiland to step down as President and Chief Executive Officer in order to return to Denmark with his family

Zacks Investment Research - 10 months ago

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 11 months ago

Radius (RDUS) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2019 as Tymlos gains traction.

Seeking Alpha - 11 months ago

Radius Health, Inc. (RDUS) CEO Jesper Høiland on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Radius Health (RDUS) delivered earnings and revenue surprises of 27.03% and 4.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

About RDUS

Radius Health, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in phase 3 clinical study for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time patch, that is in phase 3 clinical study to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen rec... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jun 6, 2014
CEO
G. Kelly Martin
Employees
383
Stock Exchange
NASDAQ
Ticker Symbol
RDUS
Full Company Profile

Financial Performance

In 2019, Radius Health's revenue was $173.32 million, an increase of 74.65% compared to the previous year's $99.24 million. Losses were -$132.99 million, -39.91% less than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Radius Health stock is "Hold." The 12-month stock price forecast is 22.14, which is an increase of 11.82% from the latest price.

Price Target
$22.14
(11.82% upside)
Analyst Consensus: Hold